Fusion Protein Technologies for Biopharmaceuticals (eBook, ePUB)

Applications and Challenges
Redaktion: Schmidt, Stefan R.

• Format: ePub

Produktbeschreibung

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs--with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins--receptor-traps, immunotoxins, Fc-fusions and peptibodies--while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: John Wiley & Sons
• Seitenzahl: 672
• Erscheinungstermin: 28. Januar 2013
• Englisch
• ISBN-13: 9781118354582
• Artikelnr.: 37757955

Autorenporträt

STEFAN R. SCHMIDT, PhD, is Vice President for Downstream Processing at Rentschler Biotechnology. Previously, he served as CSO at ERA Biotech and Associate Director for Protein Science at AstraZeneca. Dr. Schmidt has chaired many international conferences and written several original articles, reviews, and book chapters.

Inhaltsangabe

PREFACE xxiii CONTRIBUTORS xxv PART I INTRODUCTION 1 1 Fusion Proteins: Applications and Challenges 3 Stefan R. Schmidt References
18 2 Analyzing and Forecasting the Fusion Protein Market and Pipeline 25 Mark Belsey and Giles Somers Disclaimer
36 Acknowledgment
36 References
36 3 Structural Aspects of Fusion Proteins Determining the Level of Commercial Success 39 Giles Somers References
54 4 Fusion Protein Linkers: Effects on Production
Bioactivity
and Pharmacokinetics 57 Xiaoying Chen
Jennica Zaro
and Wei-Chiang Shen References
71 5 Immunogenicity of Therapeutic Fusion Proteins: Contributory Factors and Clinical Experience 75 Vibha Jawa
Leslie Cousens
and Anne S. De Groot Acknowledgment
87 References
87 PART II THE TRIPLE T PARADIGM: TIME
TOXIN
TARGETING 91 IIA TIME: FUSION PROTEIN STRATEGIES FOR HALF-LIFE EXTENSION 93 6 Fusion Proteins for Half-Life Extension 93 Stefan R. Schmidt References
104 7 Monomeric Fc-Fusion Proteins 107 Baisong Mei
Susan C. Low
Snejana Krassova
Robert T. Peters
Glenn F. Pierce
and Jennifer A. Dumont References
118 8 Peptide-Fc Fusion Therapeutics: Applications and Challenges 123 Chichi Huang and Ronald V. Swanson Acknowledgment
138 References
138 9 Receptor-Fc and Ligand Traps as High-Affinity Biological Blockers: Development and Clinical Applications 143 Aris N. Economides and Neil Stahl Acknowledgment
155 References
155 10 Recombinant Albumin Fusion Proteins 163 Thomas Weimer
Hubert J. Metzner
and Stefan Schulte Acknowledgment
174 References
174 11 Albumin-Binding Fusion Proteins in the Development of Novel Long-Acting Therapeutics 179 Adam Walker
Grainne Dunlevy
and Peter Topley References
189 12 Transferrin Fusion Protein Therapies: Acetylcholine Receptor-Transferrin Fusion Protein as a Model 191 Dennis Keefe
Michael Heartlein
and Serene Josiah References
198 13 Half-Life Extension Through O-Glycosylation 201 Fuad Fares References
207 14 ELP-Fusion Technology for Biopharmaceuticals 211 Doreen M. Floss
Udo Conrad
Stefan Rose-John
and JEURurgen Scheller References
222 15 Ligand-Receptor Fusion Dimers 227 Sarbendra L. Pradhananga
Ian R. Wilkinson
Eric Ferrandis
Peter J. Artymiuk
Jon R. Sayers
and Richard J. Ross References
234 16 Development of Latent Cytokine Fusion Proteins 237 Lisa Mullen
Gill Adams
Rewas Fatah
David Gould
Anne Rigby
Michelle Sclanders
Apostolos Koutsokeras
Gayatri Mittal
Sandrine Vessillier
and Yuti Chernajovsky Acknowledgments
249 References
249 IIB TOXIN: CYTOTOXIC FUSION PROTEINS 253 17 Fusion Proteins with Toxic Activity 253 Stefan R. Schmidt References
265 18 Classic Immunotoxins with Plant or Microbial Toxins 271 Jung Hee Woo and Arthur Frankel References
286 19 Targeted and Untargeted Fusion Proteins: Current Approaches to Cancer Immunotherapy 295 Leslie A. Khawli
Peisheng Hu
and Alan L. Epstein Acknowledgments
310 References
310 20 Development of Experimental Targeted Toxin Therapies for Malignant Glioma 315 Nikolai G. Rainov and Volkmar Heidecke Disclosure
325 References
325 21 Immunokinases 329 Stefan Barth
Stefan GattenlEURohner
and Mehmet Kemal Tur References
334 22 ImmunoRNase Fusions 337 Wojciech Ardelt References
347 23 Antibody-Directed Enzyme Prodrug Therapy (ADEPT) 355 Surinder K. Sharma Acknowledgments
361 References
361 24 Tumor-Targeted Superantigens 365 Gunnar Hedlund
GEURoran Forsberg
Thore Nederman
Anette Sundstedt
Leif Dahlberg
Mikael Tiensuu
and Mats Nilsson References
379 IIC TARGETING: FUSION PROTEINS ADDRESSING SPECIFIC CELLS
ORGANS
AND TISSUES 383 25 Fusion Proteins with a Targeting Function 383 Stefan R. Schmidt References
393 26 Cell-Penetrating Peptide Fusion Proteins 397 Andres Mu~noz-Alarcon
Henrik Helmfors
Kristin Karlsson
and EURU lo Langel Acknowledgments
406 References
406 27 Cell-Specific Targeting of Fusion Proteins through Heparin Binding 413 Jiajing Wang
Zhenzhong Ma
and Jeffrey A. Loeb References
424 28 Bone-Targeted Alkaline Phosphatase 429 Jose Luis Millan Acknowledgments
437 References
437 29 Targeting Interferon-a to the Liver: Apolipoprotein A-I as a Scaffold for Protein Delivery 441 Jessica Fioravanti
Jesus Prieto
and Pedro Berraondo References
448 PART III BEYOND THE TRIPLE T-PARADIGM 453 IIIA NOVEL CONCEPTS
NOVEL SCAFFOLDS 455 30 Signal Converter Proteins 455 Mark L. Tykocinski References
468 31 Soluble T-Cell Antigen Receptors 475 Peter R. Rhode Acknowledgments
490 References
490 32 High-Affinity Monoclonal T-Cell Receptor (mTCR) Fusions 495 Nikolai M. Lissin
Namir J. Hassan
and Bent K. Jakobsen Acknowledgments
504 References
504 33 Amediplase 507 Stefano Evangelista and Stefano Manzini Acknowledgment
517 References
517 34 Breaking New Therapeutic Grounds: Fusion Proteins of Darpins and Other Nonantibody Binding Proteins 519 Hans Kaspar Binz Acknowledgments
526 References
526 IIIB MULTIFUNCTIONAL ANTIBODIES 529 35 Resurgence of Bispecific Antibodies 529 Patrick A. Baeuerle and Tobias Raum References
541 36 Novel Applications of Bispecific DART1 Proteins 545 Syd Johnson
Bhaswati Barat
Hua W. Li
Ralph F. Alderson
Paul A. Moore
and Ezio Bonvini References
554 37 Strand Exchange Engineered Domain (Seed): A Novel Platform Designed to Generate Mono and Multispecific Protein Therapeutics 557 Alec W. Gross
Jessica P. Dawson
Marco Muda
Christie Kelton
Sean D. McKenna
and Björn Hock Acknowledgments
567 References
567 38 CovX-Bodies 571 Abhijit Bhat
Olivier Laurent
and Rodney Lappe References
581 39 Modular Antibody Engineering: Antigen Binding Immunoglobulin Fc CH3 Domains as Building Blocks for Bispecific Antibodies (mAb2) 583 Maximilian WoisetschlEURager
Florian REURuker
Geert C. Mudde
Gordana Wozniak-Knopp
Anton Bauer
and Gottfried Himmler Acknowledgments
588 References
589 40 Designer Fusion Modules for Building Multifunctional
Multivalent Antibodies
and Immunoconjugates: The Dock-and-Lock Method 591 Edmund A. Rossi
David M. Goldenberg
and Chien-Hsing Chang References
599 INDEX 603